Hetrombopag Olamine for Low Platelet Count

This trial tests a new treatment called Hetrombopag Olamine for individuals with low platelet counts due to chemotherapy. The goal is to determine if this treatment is safe and more effective than a placebo (a pill with no medicine) for cancer patients undergoing certain types of chemotherapy. The trial will compare the effects of Hetrombopag Olamine to a placebo across different groups. Individuals with solid tumors, such as lung or breast cancer, who experience low platelet counts from their current chemotherapy, might be suitable candidates for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking advancements in cancer treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that hetrombopag olamine is generally safe for people. In earlier studies, most patients handled the treatment well. Serious side effects occurred in only about 5.4% of patients, including a drop in platelet counts and gum bleeding, but such events were uncommon.

Common side effects were mild, such as colds, which appeared in 57.9% of patients compared to 45.2% in those who took a placebo. The treatment has also increased platelet counts, which is important for patients with low levels.

Researchers are excited about Hetrombopag Olamine because it offers a novel approach to treating low platelet count. Unlike standard treatments like corticosteroids or immunosuppressants, Hetrombopag Olamine is designed to directly stimulate the production of platelets through a new mechanism. This could potentially lead to more efficient and targeted treatment, reducing the need for broad-spectrum therapies that often come with significant side effects. Additionally, its potential to be more effective in a shorter timeframe could greatly improve the quality of life for patients dealing with this condition.

Research has shown that Hetrombopag Olamine can increase platelet counts in people with immune thrombocytopenia, a condition where the immune system mistakenly attacks platelets. In studies, patients taking Hetrombopag had higher platelet levels than those taking a placebo, which contains no active medicine. Specifically, one study found that 43.9% of patients treated with Hetrombopag experienced lasting improvement, while none in the placebo group did. The treatment also lowered the risk of bleeding and reduced the need for other treatments. This trial compares Hetrombopag Olamine with a placebo to further evaluate its effectiveness in managing low platelet counts caused by chemotherapy.¹³⁵⁶⁷